In a clinical trial, a participant develops QT prolongation after starting a study drug. Which pharmacological mechanism most commonly causes this adverse effect?
-
A
Inhibition of hERG potassium channels
-
B
Activation of sodium-calcium exchangers
-
C
Blockade of L-type calcium channels
-
D
Inhibition of HCN pacemaker channels